

EST AVAILABLE COPY

Specific gabapentin binding (cpm)




FIG. 3

R217A WILD TYPE Mice (N = 7)

Vehicle Pregabalin

p < 0.05 (t-test: relative to vehicle-treated controls)

Treatment (100 mg/kg PO @ - 120 min)

FIG. 4B

R217A WILD TYPE Mice (N = 7)

Time spent licking (seconds)

Time spent licking (seconds)

100

*

50

0

150

200

Early Phase (0-10 min)

p < 0.05 (t-test: relative to vehicle-treated controls)

Treatment (100 mg/kg PO @ - 120 min)

R217A HETEROZYGOTE Mice (N = 7-8)

200 |-

Early Phase (0-10 min)

150

Vehicle Pregabalin

0

p < 0.05 (t-test: relative to vehicle-treated controls) Treatment (100 mg/kg PO @ - 120 min)

R217A HETEROZYGOTE Mice (N = 7-8)

Time spent licking (seconds) Vehicle Late Phase (11-45 min) Pregabalin


Time spent licking (seconds)

100

50

p <0.05 (t-test: relative to vehicle-treated controls) Treatment (100 mg/kg PO @ - 120 min)





Time spent licking (seconds)

100

50

no significant differences between Vehicle

no significant differences between Vehicle

and PGB-treated groups

Treatment (100 mg/kg PO @ - 120 min)

and PGB-treated groups

Vehicle

Treatment (100 mg/kg PO @ - 120 min)

200 |-

150





FIG. 6



BEST AVAILABLE COPY

+

FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B

